A study to see if everolimus can enhance immune response to vaccination in the elderly.
A multicenter, single-blind, placebo-controlled study to investigate effects of everolimus on the immune response to vaccination in the elderly.
Novartis Institutes for BioMedical Research, Inc.
210 participants
Jan 9, 2012
Interventional
Conditions
Summary
A multicenter study to see if everolimus has an effect on the immune response in elderly people.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Elderly participants who meet eligibility during the 21 day screening period will be randomised to 1 of the treatment arms: Arm 1 Evrolimus 0.5 mg by mouth daily or unmatched placebo Arm 2 Everolimus 5 mg by mouth weekly or matched placebo Arm 3 Everolimus 20 mg by mouth weekly or unmatched placebo During the screening period the Study Doctor will ask you about your health and your medical and (psychiatric) history. The doctor will do a physical exam and measure your height, weight, blood pressure, heart rate and breathing rate. You will be asked about any medications you have been taking. You will have a heart tracing (electrocardiogram [ECG]) and blood and urine will be taken for laboratory testing. You will have a chest X-ray done if you haven’t had one in the last 3 months.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611001241921